Brise Pharma

Based in Shanghai, China and founded in 2021, Brise Pharma operates as an innovative biomedical research and development company, focusing on developing innovative biomedical products. In November 2025, Brise Pharma closed series A funding led by returning investor Shunxi Fund, with participation from new investors INCE Capital, Geuniom Group and Proxima Ventures and returning investor Qiming Venture Partners. The company focuses on oncology and chronic disease field. Based on human genetic and pathological mechanisms to select optimal drug treatments and delivery routes.

The Company also builds its pain therapeutic pipeline through a combination of in-house research, co-development and merge, and uses clinical trial strategies to expand the accessibility and commercial value of its drugs. The company generates revenue by providing innovative drugs in the field of pain treatment. The company will use the pre-series A+ funding for the development of the pain treatment drug product pipeline in the preclinical and clinical stages, in particular to accelerate the progress of the clinical trials of the BR005 program, a small molecule drug in the CGRP (calcitonin gene-related peptide) class, which was developed and entered into the clinic.